AxoGen price target raised to $50 from $42 at Citizens

Citizens raised the firm’s price target on AxoGen (AXGN) to $50 from $42 and keeps an Outperform rating on the shares. The bullish view on AxoGen is driven by its differentiated nerve repair portfolio, including AxoGuard and Avive+, and the expected approval of Avance, which could establish it as a standard-of-care with a long competitive runway, the analyst tells investors in a research note.